Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Also recommend the share centre, 1% or 2.50min to buy batch or 7.50 instant.
Sells 7.50. Quick efficient and deals done in seconds. The one downside is unable to real-time trade until after 8.15am or after 4.15pm.
You can set-it up in 24hours and your off and running.

ethel, I use ComDirect and wont hear a word said against them - well not many anyway. You can set up electronic trades to buy/sell if a stock reaches a certain price whci usually works faultlessly.

Comdirect for me.

andysmith - Don't like the idea of missing the first and last 15 mins of trading. There's good moves made at those times. Wonder if Share Centre keep some stuff in-house.

Is this still the bioprogress thread. Just checking :-)

Thankyou all very much for the kind advice.No more chit chats with Mr P when I ring up in a hurry to do a trade and he wants to talk about road rage.I shall miss him.The old fashioned broker,still buying mainly the Footsie 100 and unwilling to take risks:the only problem is that commission plus his complete ignorance of the small caps.Ether

This is showing well of late,could a 1.20 be back on the cards soon.

Glad I topped up yesterday at 78p :)

http://www.wallstreetreporter.com/profiles/AXMPharma.html


Here is my transcript of the interview. Ive edited out the umms and aahhs to make it read better and edited the punctuation as well.

For those who dont know, Bioprogresss products will be on sale in about two weeks time in China marketed through the Sunkist brand via AXM Pharma.



WallStreetReporter interview with Douglas C. MacLellan. Vice Chairman of AXM Pharma.

Dated: February 16th 2005


IAN: Good-day from Wallstreet and welcome to all our listeners to the
WallStreetReporter. This is Ian Roberts, Senior Analyst with the WallStreetReporter. Today our featured company is a global pharmaceutical company involved in the marketing, distribution of pharmaceutical products in China. The company produces markets and distributes medicines in various dosages and forms in most areas of medicinal treatment as well as herbal remedies, vitamins and adjunctive therapies. The name of the company involved here is AXM Pharma Incorporated. AXM Pharma trading its shares on the American stock exchange; the symbol AXJ.

And joining me to discuss AXM Pharma in light of recent initiatives and strategies for 2005 and beyond is Doug Mac Lellan, the Vice-Chairman of AXM Pharma Incorporated. Doug, good morning, welcome to WallStreetReporter,

DOUG: Good morning.

IAN: For those members of our audience who havent followed AXM Pharma in its history, lets start with an overview with a time-line please.

DOUG: Well, we started building a state-of-the-art plant in Xiang-yang China which is the fifth largest city in China but it is located at northeastern part of China just above Beijing. We started building that plant about two and a half years ago and went on-line with it literally last month. Its a state-of-the-art pharma production facility and were quite proud of the progress weve made with that.

We got a ten year operating history where we were manufacturing products in an old Chinese plant, but this is a world-class plant that really has the ability to produce an enormous amount of production for us. In fact it is an in-licensing platform for production because we the ability to build up to 170 million year in sales just through that single plant.

IAN: Very interesting, and taking a look at the Company, lets take a step back here and talk about this market. You know, what is the market that is defined in China as, and what are the opportunities that you see as driving this growth opportunity?

DOUG: Well, I think theres been and certainly a lot of talk on the street about trying to enter the Chinese market. From a professional stand-point, Ive been going to China for over 22 years, so I have, you know, myself and a lot of other members on our management team and Board have an enormous experience working with China.

The magnitude of the size of the market there is of course the driving force. You know, in the United States here we have 9 cities with a population of over 1 million people. In China theyve got, you know, 163 cities that have over a million people in it. And, its just a staggeringly large market with 1.4 billion people. Also the Chinese consumer market is much larger than most people think and more affluent than most people think. Today there are over 100 million Chinese managers that make over $40 000 a year. And that is the base to which we look to market our product.

IAN: Very interesting, and talking a bit about this, lets talk about the companys recent initiatives. I understand that you have opened a new state-of-the-art facility. Tell us a bit more about this and how it advances the companys mission.

DOUG: Well, our goal is as the market has changed in China and since the signing of WTO, China has begun to enforce much more stricter regime of quality controls which lead us to build a new state-of-the-art facility that needs Chinese GMP standard. In fact all plants in China today must meet that. That traded by the way a consolidation in the industry. Last year in 2004 there were probably about 6000 pharmaceutical plants and today on estimates there are approximately 2200, of which were one.

So there has been an enormous consolidation of quality in the market place and I guess our point is were competing on, or better than, these other facilities that are available in China. And the first part of doing any business in China is to make a good product and were in this position to do that. And the next thing of course, is to have a good set of products to manufacture and to have a good distribution network to get the products to the market place. We think were effectively in 2005 are going to hit all those things in a way that drives sales in a strong pattern.

IAN: Exceptional. Lets focus now on your product and line of products. Particularly I note that the highlights there with your Sunkist products. Tell us a bit more about this and the market opportunity you see outlined.

DOUG: Sure. AXM has licenses to produce 43 different products. Of those licenses today, were making about 3 or 4 products out of those licenses. In addition to that weve introduced some new products. Well be expanding off our old licenses and adding new ones as we go forward. We have a feminine hygiene product today thats in the market called Whisper. We have a product called Aspron (?) for respiratory infection. We have a skin and acne treatment. We are also of course, bringing in childs vitamins and supplements which you know, is really the largest driver for us in sales in 2005. And those supplements and vitamins come through us a licensing agreement, an exclusive licensing agreement we have with Sunkist trademark for originally for China but now we have expanded it for Hong Kong and Taiwan.

Sunkist ranks in the top 25 brands in China and similarly in Hong Kong and Taiwan.
And we expect to have a very strong showing in that category and that includes vitamins in product strip products which are similar to Listerine products except they have therapeutic elements to them. Either they are Vitamin C., Euchanasia or they are cold and flu season and its really a very effective delivery system for us. But our goal is that by the end of the first quarter or the beginning of the second quarter we should have up to 13 products out in the market selling those. And we expect to see significant growth because of that

IAN: Now Looking at the line of products you mentioned, the growth drivers there, what are the other things that we should note here in the strategic steps necessary to ensure success. I understand that regional distribution partners will play a substantial part in that role. Can you give us a sense in where you stand in these efforts?

D.M: Sure. There is like in any business, there is the cost if distribution. In traditional markets like the United States there are times when many companies can do their own distribution effectively. I would say that in China first of all, regulatory it was required that all pharma companies utilize third party distributors. That has slightly changed over the last year but for us to be effective in going to market quickly we needed to use third party, and continue to use third party distributors.

Now in prior years we had a very small regional distributor out of Chang Chun (?) Province. Last year we signed an in-depth agreement with China Zuellig which is a subsidiary of Interpharma Group which is the largest pharmaceutical distributor in Asia with an annual revenues exceeding $3 billion. And they are pushing very hard for us, particularly on the Sunkist brand of products in China, Hong Kong and Taiwan. And you know, our relationship with them and theirs with us, we think bodes well for us to drive sales particular with those product lines.

We also expect to be selling direct in some cases to several large chain-store pharmacies depending on the product line. And we are likely to sign up to one or two additional nationwide distributorships with Chinese distributors with certain of our products. So we will be expanding off now with what we have built up with Zuellig but again, it will position us to have a really strong 2005.

IAN: Lets talk about this 2005. In terms of looking at the product offering, what are some of the things we should expect to see and understand of the companies growth prospects. What are the major milestones youve outlined?

DOUG: Well, I think first of all well start seeing product coming out of our plant and ramping up inventory during this 1st quarter. Then moving into the 2nd quarter we expect to see significant sell-through in our products through our distributors and that should continue throughout the year in a significant pace. We arent putting out any guidance yet for numbers but we think we going to have a very significant year and one that should be profitable.

IAN: Lets talk a bit about the infrastructure of the company and talking a bit about management and the team you have assembled. What are the things we should know about the people behind the mission and what additions have you made recently that may enhance the company and its strategy.

DOUG: Well, I think building human capital or management teams is always a difficult thing and a challenge in emerging markets and businesses and cross-border businesses. We did several things this year in that we rearranged some of the authorities and responsibilities of our management. One of the key things was that we shifted responsibility for international sales of our Sunkist product line strictly to Peter Cunningham who has got a very strong background, who was formally our CEO and is now president of international sales.

We also then took a gentleman who has got a significant amount of management experience and senior management experience, Chep(?) Howard who was our CFO and made him CEO and also acting CFO until hiring a new replacement for that spot. And I think notably we also have hired Zemyou Kong (?) who is the formallyor who is retiring as president of China operations for Sino Pharm which is Chinas largest manufacturer and distributor in China and we expect him to be very helpful in all of our China operations, particularly in sales and marketing. And he will be coming in as president of China Ops or operations and CEO of AXM Shenyang which is our operating subsidiary in China.

And lastly we have a very strong chief technical officer, Chris Gee(?) who has been with the Group but has got an enhanced role in really actively building a monitoring system for us internally for our sales and distribution activity.

IAN: Interesting. And looking in light of your business model and recent news, talking a bit about capitalizing on this explosive growth rate, what are the things that we should note here about this market in particular, in terms of trends that you feel may shape the way you accelerate or accomplish your mission?

DOUG: Well, we had a very difficult transition year in 2004 where we were completing our manufacturing facilities. We were completing compliance in all our new sales regulations and licensing regulations for our products and it was really an enormous transition year for us and it took more work than we thought it would. In 2005 all the work we put in 2004 kind finally hits the road and gives us some significant traction in just getting back to being a good strong business with good sales and earnings that are interesting.

IAN: In terms of understanding this do you feel the investor community a whole understands the company and its position to capitalize on the opportunities for growth in this market?

Doug: Well, I think the way we have structured our business unlike many Joint-Ventures in China or as listing as an ADR or some other foreign issuer. We are an American issuer with 100% China operations. We think that and our structure as a wholly owned foreign enterprise in China is unique and we think our model will be used by other Chinese companies in the years to come. We think we have created one that creates more transparency and is easier to understand and look at. I think the investing public is slowly starting to take a look at us and in 2005 with posting some reasonably good numbers our prospects will be changing significantly and the profile of the company will. And I think that will attract some interest. So today we have got a heck of a buying opportunity because we are probably under the radar screen.

IAN: Very interesting to note here. Also, in light of the issue of possible competition. What are the prospects for the company to succeed as you outlined here in light of the possibility of competition entering the market here in 2005?

DOUG: Well, there is a lot of competition in China. The things that make us unique are things like our Sunkist brand that other companies dont have. That Western branding products is a significant driver. We also areour licenses that we have are fairly unique and we do have some products that have some history of having some good sales for instance our product which is for respiratory condition.

So we think we can regain the momentum of those sales of traditional products and also our new products are highly unique. They also take fairly unique manufacturing conditions to make these products which again makes it harder for someone to directly compete against us.

IAN: Very interesting. And in closing words here to our audience, what would you highlight foremost to show us out there. What is the most compelling reason to own or participate in AXM Pharma in 2005 or beyond that date?

DOUG: I think if we can hit our internal plans for sales in by comparison with other international pharmaceutical companies, certainly we are at a price that is at a lot lower valuation than we see everybody else. And we think we will grow in to a much stronger valuation and which today makes us something that people should watch and maybe buy.

IAN: Certainly a fascinating company to follow here. Certainly positioned well to capitalize on the market opportunity in the Chinese over-the-counter pharmaceutical market. I would like to thank my guest Doug MacLellan, the vice chairman of AXM Pharma for taking the time to present us with an update portrait on the company and strategy in moving ahead. Doug, we wish you the best of success there.

DOUG: Thanks for letting me join you . (etc).

Whew!!!!Well done.Does AXM use BPRG films?

phew! amazing, thanks! the only way is up!

Where?

Click Here

Why isnt this stock getting more attention.Good news could be imminent...

This was posted on A-D-V-F-N today.


- 26 Feb'05 - 06:25 - 45200 of 45237


OK, HERE IT GOES, ENJOY HAVE A NICE ONE


"BIOPROGRESS

BPRG (LSE)

RELEASED FEB 25, 2005

FOR GDPAH CLIENTS ONLY




INTRODUCTION

The company clearly has disruptive technology that has passed the thoughest inspection for small companies in the world "blue chip pharma", for a market starving for innovation in order to reduce cost, extend patent protection, reduce health concerns regarding BSE and offer innovative solutions and products, with potentially several multimillion sources of revenue, blue chip pharma partners like FMC, Perrigo, Bristol Myers Squibb, Wyeth, among others, exiting products already selling extremely well such as Maxfresh with Colgate, Cold strips, vitamine strips with the sunkist and boots brands, to name a few. It has recently won a landmark case in patent law against Stanelco SEO (LSE) which has been financed by fortune 500 CARDINAL HEALTH CAH (NYSE) who seems very afraid of loosing Wyeth which is one of its most important customers hence a luxury CAH is unable to afford particularly now after a very unfortunate set of results. Wyeth and BPRG have been developing new products and have succesfully finished a due dilligence procedure and are currently negotiating an exclusive worldwide licence to acquire the rights to bprgs tabwrap. Ontop bprg is expected to begin production later this year of the first nicotine strip in the world.


NEWS FLOW

The company informs the market at least quarterly about its products, negotiations etc, in compliance with Nasdaq regulations. However, due to confidentiallity agreements both bprg and its blue chip clients tend to inform the markets about especific products until or after they are actually commercialised. In some cases like the sunkist agreement for China, Taiwan and the rest of Asia the information becomes public few weeks before official commercialisation, in others like the cold strip -already in sale in the US- the name of the partner has been kept secret, there is also the Colgate case where the deal, was disclosed after a few weeks of it been commercialised in America. In the later case Colgate has announced that maxfresh has contributed significantly to a sharp increase in revenue from toothpaste and there is mounting especulation that Colgate will take it globally soon. The company is currently in a closed period as results and updates and new contracts on several fronts are expected in march, nevertheless the exact timing for news release is difficult to anticipate could be in the comming days or weeks. There seems to be a number of important news in the near future that could have a quantum leap effect on the volumes and current and former trading ranges.


PRODUCTION CAPACITY

This issue is usually of concern, especially when a small capitalisation company is able to close deals with the big players. In BPRGs business model this is not a problem. BPRG instead of spending millions in the construction of new plants has pulled a few Trumphs, consisting basically in the acquisition of two production lines at a heavily discounted price and has also acquired a plant in Tampa Bay, Florida USA, at an extremely reduced price. Both aquisitions certainly remind us of a few tricks performed by the Donald in his early years. BPRG has also managed to have 15 million pounds in the bank, while providing assurance to their blue chip clients that it has the production capacity and flexibility required to meet their global production needs trough a strategy named "locum".


INSIGHT

This share suffers as many others in the English AIM market by the presence of what seems a very well organised group of derampers whose financing and intentions are the object of several conspiracy theories, which in many cases lead to CAH. Mainly that the later company is looking to bid for BPRG especially after the defeat it suffered through its tin puppet SEO in the English Patent Courts. The latest trading update was used by shorters and BB professional derampers to claim that the companys CEO is not to be trusted. In the third quarter of 2004 Collins Stewart -broker- issued a buy note forecasting profits of one million english pounds in 2004 and close to six million english pounds in 2006. The share price responded quite well provoking a short squeeze, taking it to a high of 135p. This was nearly eleven months into the financial year and approaching the closed period for the company. Unfortunately the 20 year rarity of several hurricanes did hit Florida during the summer in 2004. Another scaremongering from shorters and BB professional derampers consisted in crying faul when BPRGs CEO sold part of his holding to buy his daughter a house, and a rumor started by this malicious mob -currently under investigation- that the CEO had resigned. This mob evidently and for obvious reasons ommited to mention that the CEO excersiced 100k options immediately after his sell and that he has several million of options upon the meeting of several juicy and not remote targets. The share price pressure by another short raid forced the company to obtain authorisation from some of its patners and clients to disclose some information, although modestly. The highlight of the trading update is that WYETH has finished the due dilligence procedure succesfully and is negotiating a global exclusive licencense with BPRG which produced another short squeeze.

Unfortunately for the company the mob continued using their scaremongering tactics helped by paryticularly rare Market Marker performance mainly from Winterfloods. However the mob maliciously avoided to mention that the loss was due to climate conditions not seen in Florida for the last 20 years and most importantly that the main reason for the loss of revenue was due to the fact that bprg has decided to cancel the production of tobacco related products that the company that they acquired in Florida used to produce, because tobacco products and big pharma simply do not go together. Critics have also failed to mention that to compensate the loss of revenue from tobacco related products, BPRG is developing a nicotine strip with a blue chip US pharma and Micap another AIM LSE company. The mob maliciously ommits to mention that 2005 will not only see revenue comming from the Tampa Bay Plant, but also, from their ostomy pouch -the only flushable in the world- NROBE, maxfresh, sunkist, cold strip, nicotine strip, Tabwrap, SEPTUM, among many others. Another scaremongering tactic claims that Collins Stewart have now withdrawn their note -which is true partially- and are not issuing an update, which is incorrect as it is our understanding that the broker is updating its buy note to take into account the hurricane issues and the new contracts announced since then so that the estimates are able to accommodate for a possible 10 million pouds profit in 2005 alone. There are other scaremongering tactics by critics an interesting one that has resulted in the appointment of not only one but two new board memebers, is that which claims that the CEO is financially incompetent or else. This has led bprg to appoint newmwmbers with an excellent city reputation for their finance experience and abilities and another who is a qualified solicitor.

TECHNICAL INDICATORS

Currently all indicators are positive. After a bear raid that took it to the very oversold ground, the share price has recently begun an uptrend on the back of 1 golden cross and most importantly the 20 MA seems to be ready to take on the 200 MA with the 50 MA following suit shortly after.


PERSPECTIVE FOR 2005

Bprg not only has one of the most fantastic potentials in the Alternative Investment Market in London and offers the american investor the possibility to enter the English AIM without leaving New York or having to open a London account, since BPRGs shares are listed in the NASDAQ as well. This is an investment opportunity that must be serioulsy considered, not only for what BPRG is currently negotiating or developing but also due to the products already been commercialised extremely succesfully. Despite the continuing scaremongering -under investigation- and the ocasional Market Marker games it has managed to continue to make progress and 2005 is already looking like a very interesting proposition at least.


Our price target for 2005, was a consuming and a difficult but fascinating endevour, the magnitude of the undergoing proyects with FMC, WYETH, Bristol etc, etc, is so impresive and when we included the projections from the ostomy pouch, nicotine strip, cold strips, and sunkist it was absolutely mind blowing based on the curent sales of capsules, tablets, nicotine patches, gums, vitamins and ostomy pouches the numbers where absolutely insane. However as for now we decided that a target price of five british pounds per share is reasonably conservative and easily achievable in 2005, because the revenue sources are so many and in markets worth billions of dollars. For instance the FMC deal has on its own, the potential of providing BPRG with sufficent turnover in 2005 to justify our target in for that year, not to mention the effect that the Wyeth license will have again on its own on the share price. If and when all those propositions become reality even at a 25% of their potential this company could be one of the biggest in terms of market capitalisation in the UK and the USA. This share in our opinion has the potential of becoming one of the AIMs best performers in 2005. A must have in every growth portafolio.

EDA
IMP"
------------------------------------------

sirjc - 26 Feb'05 - 15:01 - 45257 of 45286


Dear all

The note was mailed to me by a good friend of mine. it is a translation -not by me-. It is my understanding that it was released originally in German and translated into English, French and Spanish, the broker mainly deals with wealthy germans and has offices in America, France and Spain. It is not available to the public and I might have lost a very good and extremely wealthy friend for my indiscretion.

Anyway as I said enjoy, I know I did, and whether the price target is right or wrong time will tell. I am ringing CS on monday to verify if they are actually rewriting their note. For now in my mind until news are released the answer is in the wins, as I said they rule.

Soul inspiring,Bloodhound.Thanks for sharing that one with us.Do you think that CAH is going to bid for BPRG?Incidentally,why have Micap's shares got stuck down so low at 28.50(bid 27/offer30)?Is it because of the 8 million sterling mk.cap?Even the announcement of the recent acquisition of Rendel and Scherer Gbr. failed to move the sp.How much have SKP invested in BPRG and what arrangements do they have with them?Thanks,Ethel

Well, that failed to inspire.........or amI being cynical?

Failed miserabley.
Im now out of this stock. Thanks for the short very unexciting ride, bit like going from Covent Garden to Paddington on the tube.

Yes, it ain't the stock it used to be, is it?

;-)

Prelims are 8/3/2005 and Annual report 9/3/2005. AGM 23/4/2005. I would think there will be little movement until the 9th.

Patience is a virtue, but it can be expensive!